VANCOUVER, BC / ACCESSWIRE / April 27, 2017 / Vangold Resources Ltd. (“Vangold”) (TSX-V: VAN) (OTC PINK: VNGRF) is pleased to announce the closing of its acquisition of a 100% interest in the El Pinguico Property and historic mine located 10 km from the City of Guanajuato, Mexico (the “Acquisition”) – see news release dated January 05, 2017.

Under the terms of the acquisition, Vangold has acquired 100% ownership of rights and title to the El Pinguico mining claims #166665 and #165491, totaling 71 hectares. Pursuant to the Acquisition, the Company has paid US$100,000 and issued 5,000,000 common shares to the vendors, Exploraciones Mineras Del Bajio, SA de CV (EMDB) and will issue 662,500 common shares as a finder fee. All securities issued will be subject to a hold period expiring August 27, 2017.

Cameron King, President and CEO, of Vangold said, “I would like to take this opportunity to personally thank EMDB for their continuous support in working towards the closing and bringing this valuable asset into Vangold. Our shareholders have also provided the Company great support and confidence in our corporate strategy of purchasing undervalued silver and gold properties with a focus of unlocking the true potential of these assets through continuous exploration and mine development.”

ABOUT “EL PINGUICO MINE”

Once one of Mexico’s most prolific silver and gold mines with grades over 9 g/t Au and over 900 g/t Ag, with a 15 g/t Au eq. cutoff grade, as documented assays found in the detailed mine development plans performed between 1906 to 1910. Technical reports issued in 1907 by experts in the different areas (geology, mining, metallurgy and finance) provide documented evidence of the once profitable producer. [Prof. Robert T. Hill, 1910, Report upon the Properties of The Pinguico Mines Company, The Securities Corporation Ltd. NY, NY]. In 1913, due to the Mexican Revolution, the El Pinguico Mine ceased operations, leaving behind several hundred thousand tons of broken ore in the underground stopes and the unmined vein system continuing at depth and length.

Through several gold and silver cycles since the turn of the Century, The Pinguico mine has been a point of discussion to be put back into production. In 1959, an extensive geological assessment was undertaken, assays grade average of 2.72 g/t Au and 251 g/t Ag were reported, with various samples throughout the underground stock pile showing grades over 5 g/t Au and 500 g/t Ag (CRM Mexican Geological Survey 1959, ESTUDIO GEOLOGICO MINERO DE LA ZONA “EL PINGUICO” DISTRITO MINERO DE GUANAJUATO, GTO, Authors: Ing. Edgardo Meave T., Ing. Juan M Gómez, Ing. José Nava Arrieta).

Not until 2012 was there additional work conducted in the mine, a sizeable assay program and mine plan development was led by Exploraciones Mineras Del Bajio and undertaken by Servicio Geologico Mexicano – SGM (Mexican Geological Survey), showing a potential underground broken ore with average grades of 1.6 g/t of Au and 143 g/t of Ag. [SGM, 2012, Certificacion de Reservas Mineral Quebrado en la mina “El Carmen-El Pinguico” Municipio de Guanajuato, Gto. For qualifications and key assumptions, see the Company’s news release dated January 5, 2017].

In February 2017, Vangold performed a similar assay program under 43-101 protocols, realized an 8% improvement in grade at 1.75g/t Au and 184 g/t Ag. Of specific interest, assays from the north end trench samples F-001 to F-005, of the underground stock pile, report a range of 3.78 g/t Au and 558 g/t Ag to 15.70 g/t Au and 1,475 g/t Ag. These results are attributed to fines falling from the exposed Dos Estrellas vein stope onto the stock pile (Vangold 43-101 Report Feb. 28, 2017, Carlos Cham QP, filed on SEDAR April 27, 2017).

Table 13 Assay Results for 2017 Trench Samples (Samples Collected by the Author) from El Pinguico Underground Stockpile

The potential of el Pinguico claims is important, where the main targets are to explore the lower Pinguico vein below the existing old workings. Also, the potential intersection of the Pinguico vein with the Mother Vein, which has been the most important ore source of the area, producing over a billion ounces of silver since 1500’s. In addition of these 2 main targets, the exploration and understanding of the existing exposed veins such as the San Jose vein, Pachuca vein, el Pirul vein, La Joya vein, and el Pino vein have been targeted for immediate exploration programs.

ABOUT VANGOLD MINING

Vangold is a development stage silver and gold company focused on production in Mexico. Vangold is aggressively pursuing its business plan of becoming a producer through the development of its existing mineral property assets and the pursuit through acquisition of additional mineral assets which contribute to Vangold achieving its aggressive corporate growth objectives.

Qualified Persons

The disclosure of historical, scientific or technical information regarding the Property in this news release has been reviewed and approved by Mr. Hernan Dorado Smith, Director. Mr. Dorado is a Qualified Person (QP) by the Mining and Metallurgical Society of America (MMSA) as defined in National Instrument 43-101 and has reviewed and approved the contents of the news releases.

ON BEHALF OF THE BOARD OF VANGOLD RESOURCES LTD.,

Cameron King, President & CEO

Contact Information:

Vangold Resources
1400-1111 West Georgia Street,
Vancouver BC, V6E 4M3
E: cking@vangold.ca
T: +1 604 499 6545 W: www.vangold.ca

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate,” “believe,” “estimate,” “expect,” “target,” “plan,” “forecast,” “may,” “schedule,” and similar words or expressions, identify forward-looking statements or information.

These statements reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or information and the Company has made assumptions and estimates based on or related to many of these factors.

Investors are cautioned against attributing undue certainty to forward-looking statements or information. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

None of the securities anticipated to be issued pursuant to the Arrangement have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued in the Arrangement are anticipated to be issued in reliance upon available exemptions from registration requirements pursuant to Section 3(a) (10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

SOURCE: Vangold Resources Ltd.

ReleaseID: 460921

BEDMINSTER, NJ / ACCESSWIRE / April 27, 2017 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC (the “Underwriter”), as sole-book running manager, under which the Underwriter has agreed to purchase on a firm commitment basis a minimum of 13,333,333 shares of common stock of the Company, together with two tranches of warrants to purchase a minimum of 19,999,998 shares of common stock of the Company, at a price to the public of $0.75 per share and accompanying warrants.

The aggregate gross proceeds to the Company are $10 million, before deducting underwriting discounts and commissions and estimated offering expenses. All shares of common stock issued in connection with this offering will be listed on the NYSE MKT and will be freely tradable on such exchange.

H.C. Wainwright & Co. is acting as the sole book-running manager for this offering.

Each Tranche 1 Warrant will have an exercise price of $1.05 per share of common stock, will become exercisable on any day on or after the date that we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock has been approved by our stockholders and has become effective (the “Exercisable Date”), and will expire five years following the Exercisable Date. Each Tranche 2 Warrant will have an exercise price of $0.75 per share of common stock, will become exercisable on the Exercisable Date and will expire thirteen months following the Exercisable Date.

The Company has granted to the Underwriter a 30-day option to purchase up to an additional 1,999,999 shares of common stock and/or warrants to purchase 2,999,998 shares of common stock of the Company, for potentially additional aggregate gross proceeds to the Company of up to approximately $11.5 million (assuming no exercise of the warrants) before deducting underwriting discounts and commissions and estimated offering expenses.

The closing of the offering is expected to occur on or about May 3, 2017, subject to customary closing conditions. The Company intends to use the net proceeds of the offering for general corporate purposes, including the development of Neutrolin, specifically the LOCK-IT-100 and LOCK-IT-200 clinical trials, and working capital and capital expenditures.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities described above are being offered by the Company pursuant to a “shelf” registration statement, including a base prospectus, which was previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on April 17, 2015. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and the accompanying prospectus related to the offering will be filed with the SEC and once filed, copies can be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by calling 646-975-6996 or by email at placements@hcwco.com or at the SEC’s website at http://www.sec.gov.

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product, Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Neutrolin is currently in a Phase 3 clinical trial in patients undergoing chronic hemodialysis via a central venous catheter. The Company is planning to conduct its second Phase 3 clinical trial in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product. It is already a CE Marked product in Europe and other territories.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about CorMedix, including but not limited to statements with respect to CorMedix’s plans to consummate its proposed underwritten offering of common stock and warrants and the use of proceeds. CorMedix may use words such as “may,” “might,” “should,” “anticipate,” “estimate,” “expect,” “projects,” “intends,” “plans,” “believes,” and words and terms of similar substance to identify such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, whether or not CorMedix will be able to raise capital, the final terms of the underwritten offering of common stock and warrants, market and other conditions, the satisfaction of customary closing conditions related to the underwritten offering of common stock and warrants, CorMedix’s business and financial condition, and the impact of general economic, industry or political conditions in the United States or internationally. For additional disclosure regarding these and other risks faced by CorMedix, see disclosures contained in CorMedix’s public filings with the SEC, including the “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2016, and under the heading “Risk Factors” of the prospectus supplements for this offering. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and CorMedix undertakes no obligation to update such statements as a result of new information.

For Investors & Media:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

SOURCE: CorMedix Inc.

ReleaseID: 460914

WASHINGTON, D.C. / ACCESSWIRE / April 27, 2017 / The International Biometrics + Identity Association (IBIA), the preeminent trade organization for the identity technology industry, is proud to announce that The Honorable Michael T. McCaul, is the keynote speaker at its Washington, DC ‘connect:ID’ Conference and Exhibition, May 1-3, 2017. Congressman McCaul will address “Vetting, Screening and Border Security: The Role of Biometrics” on Tuesday, May 2 at 8:55 am.

Congressman Michael T. McCaul is currently in his seventh term in the U.S. House of Representatives and has served as Chairman of the House Homeland Security Committee since January 2013, where his top priorities remain shielding the homeland from the rising threat of terrorist and foreign fighters, securing the nation’s land and maritime borders, enhancing cyber defenses, making the nation’s airport security-system smarter and more efficient, and providing rigorous oversight of the Department of Homeland Security.

According to Tovah LaDier, IBIA Managing Director, “Congressman McCaul’s address on the operational challenges of securing and protecting the nations’ borders and citizens and the importance of inter-agency coordination and co-mingling of infrastructure, technology, and personnel will be of great interest to security and technology leaders in the ‘connect:ID’ audience.”

Prior to Congress, Congressman McCaul served as Chief of Counter-Terrorism and National Security in the U.S. Attorney’s office, Western District of Texas, and led the Joint Terrorism Task Force. He served as Texas Deputy Attorney General under current U.S. Senator John Cornyn, and served as a federal prosecutor in the Department of Justice’s Public Integrity Section in Washington, D.C.

‘connect:ID’ is the preeminent conference and exhibition where industry, government, and consumers join together to see the latest innovations and discuss the policy and technology issues that shape the concepts of identity. Produced by IBIA and Science Media Partners (SMP), ‘connect:ID’ will be held at the Walter E Washington Convention Center in Washington, D.C. The conference runs May 1-3. Learn more at www.connectidexpo.com.

About IBIA: IBIA advances the adoption and responsible use of technology-based identification solutions to enhance security and privacy and to facilitate convenience and productivity for government, businesses, and consumers. For more information, please visit our website www.ibia.org.

Media enquiries for IBIA: Tovah Ladier, ibia@ibia.org.

Media enquiries for Congressman McCaul: Susan Phalen, Susan.Phalen@mail.house.gov.

SOURCE: The International Biometrics + Identity Association

ReleaseID: 460897

LOS ANGELES, CA / ACCESSWIRE / April 27, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Caterpillar Inc. (“Caterpillar” or the “Company”) (NYSE: CAT) concerning possible violations of federal securities laws between February 19, 2013 and March 1, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the May
2, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also do nothing and be an absent class member.

The Complaint alleges that during the Class Period, Caterpillar issued materially false and misleading statements and/or failed to disclose: that the Company unlawfully used foreign subsidiaries to avoid paying billions of dollars in U.S. taxes; that discovery of such conduct would subject Caterpillar to heightened regulatory scrutiny and potential criminal sanctions; and that Caterpillar’s public statements were materially false and misleading at all relevant times. On March 2, 2017, law enforcement officials raided the Company’s facilities in Peoria, Illinois. The Company indicated that it believed the raid is related to export filings of its Swiss subsidiary, Caterpillar SARL. Upon announcement of this news, the stock price of Caterpillar declined significantly, which harmed investors, according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 460888

BOSTON, MA / ACCESSWIRE / April 27, 2017 / Zoom Telephonics, Inc. (“Zoom”) (OTCQB: ZMTP), a leading producer of cable modems and other communication products, announced that it will release results for its first quarter ended March 31, 2017, after the close of the market on Tuesday, May 2, 2017 and will host a conference call at 5:00 p.m. Eastern Time that evening.

Listeners may access the conference call by dialing (877) 706-2128 in the U.S. and international callers may dial (706) 643-5255. The conference ID is 14375320. A slide presentation will accompany management’s remarks and may be accessed five minutes before the conference call at www.zoomtel.com/s1. Shortly after the conference call, a recording of the call will be available on Zoom’s website.

About Zoom Telephonics

Founded in 1977 in Boston, Zoom Telephonics, Inc. designs, produces, markets, and supports cable modems and other communication products. For more information about Zoom and its products, please see www.zoomtel.com.

Company Contact:

Zoom Telephonics Investor Relations
99 High Street
Boston, MA 02110
617-753-0897
investor@zoomtel.com

Investor Relations Contact:

John Nesbett/Jennifer Belodeau
Institutional Marketing Services (IMS)
Phone: 203-972-9200
jnesbett@institutionalms.com

SOURCE: Zoom Telephonics, Inc.

ReleaseID: 460878

CHESTER, NY / ACCESSWIRE / April 27, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”), announced that the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. Accordingly, the Company will file its Form 10-K for the fiscal year ending February 28, 2017 in May 2017. For its new fiscal year ending December 31, 2017, it will file its Form 10-K for ten months ending December 31, 2017 and twelve months ending February 28, 2017 in March 2018. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March, 2017 and the quarter April through June 2017 on Form 10-Q in August 2017.

“This change is being made by the Company to better align the Company’s financial reporting calendar with its industry peers, suppliers and customers,” said Karen Fisher, RMS Chief Financial Officer. “We recognize that the fiscal-year change will involve some short-term inconvenience for those who follow our financial results, but we believe it is the right thing to do for our business, and we’re committed to providing the necessary information in a timely and transparent manner.”

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company’s website may be visited at www.rmsmedicalproducts.com.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission.

For more information, please call:

Mike King
702 650 3000
Princeton Research

SOURCE: Repro Med Systems, Inc.

ReleaseID: 460900

OLD BRIDGE, NJ / ACCESSWIRE / April 27, 2017 / Blonder Tongue Laboratories, Inc. (NYSE MKT: BDR) announced today that it will report its First Quarter 2017 financial results on Monday, May 15, 2017 prior to market opening. Management will then host a teleconference to discuss the results with the investment community.

Details of the Live Teleconference:

Date: Monday, May 15, 2017
Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)
Investor Dial-in (US & Canada Toll-Free): 866-682-6100

The audio replay will be available under Investor Related Information on the Blonder Tongue Investor Relations webpage.

About Blonder Tongue

Blonder Tongue Laboratories, Inc. together with R.L. Drake Holdings, LLC – its wholly owned subsidiary – offer customers more than 130 years of combined engineering and manufacturing excellence with solid histories of delivering reliable, quality products. As a leader in the field of Cable Television Communications, the Company provides system operators and integrators serving the cable, broadcast, satellite, IPTV, institutional and professional video markets with comprehensive solutions for the provision of content contribution, distribution and video delivery to homes and businesses. The Company designs, manufactures, sells and supports an equipment portfolio of standard and high definition digital video solutions, as well as core analog video and high speed data solutions for distribution over coax, fiber and IP networks. Additional information on the Company and its products can be found at www.blondertongue.com, and www.rldrake.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes “forward-looking” statements and accordingly, the cautionary statements contained in Blonder Tongue’s Annual Report and Form 10-K for the year ended December 31, 2016 (See Item 1: Business, Item 1A: Risk Factors, Item 3: Legal Proceedings and Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations), and other filings with the Securities and Exchange Commission are incorporated herein by reference. The words “believe,” “expect,” “anticipate,” “project,” “target,” “intend,” “plan,” “seek,” “estimate,” “endeavor,” “should,” “could,” “may” and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, our anticipated growth trends in our business and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. Blonder Tongue undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Blonder Tongue’s actual results may differ from the anticipated results or other expectations expressed in Blonder Tongue’s “forward-looking” statements.

Contacts:

Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000

Robert J. Pallé
Chief Executive Officer
bpalle@blondertongue.com
(732) 679-4000

SOURCE: Blonder Tongue Laboratories, Inc.

ReleaseID: 460896

MAYFIELD HEIGHTS, OH / ACCESSWIRE / April 27, 2017 / Materion Corporation (NYSE: MTRN) will host a conference call and live webcast to discuss the results of the first quarter 2017, to be held Friday, April 28, 2017 at 9:00 AM Eastern Time.

Live Event Information

To participate, connect approximately 5 to 10 minutes before the beginning of the event.

Date, Time: April 28, 2017 at 9:00 AM ET
Toll Free: 877-407-0778
International: 201-689-8565
Live Webcast: www.investorcalendar.com/IC/CEPage.asp?ID=175696 or www.materion.com

Replay Information

The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on May 13, 2017.

Toll Free: 877-481-4010
International: 919-882-2331
Replay ID#: 10271
Webcast: www.investorcalendar.com or www.materion.com

About Materion Corporation

Materion Corporation is headquartered in Mayfield Heights, Ohio. The Company, through its wholly-owned subsidiaries, supplies highly engineered advanced enabling materials to global markets. Products include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium alloys, beryllium and beryllium composites, and engineered clad and plated metal systems.

SOURCE: Investor Network

ReleaseID: 460793

VICTORIA, BC / ACCESSWIRE / April 27, 2017 / FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE MKT: FSI, FRANKFURT: FXT) is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment, as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today, the Company announces a year over year decrease in revenues for first quarter (Q1) 2017.

Sales were lower in Q1, 2017 than in Q1, 2016. Flexible Solutions’ top line revenue decreased from $5.30 million (Q1, 2016) to $4.66 million (Q1, 2017), down 12% year over year.

CEO, Dan O’Brien, states, “Some of the revenue shortfall, which was expected, is the result of the fire at the Taber, Alberta facility. The remainder consists of orders pushed into second quarter and one large agriculture sale lost for the year due to the customer having inventory left from 2016.” Mr. O’Brien continues, “We look forward to the rest of the year, expecting that positive news will exceed negative news and that revenue growth will resume.”

Complete financial results will be available on May 15, 2017, concurrent with our SEC quarterly filings. A conference call will be scheduled for 8:00am Pacific Time, 11:00 am Eastern Standard Time, the following day, May 16. See the FSI May 15, 2017 financials news release for the dial in numbers.

About Flexible Solutions International

Flexible Solutions International, Inc. (www.flexiblesolutions.com), based in Victoria, British Columbia, is an environmental technology company. The Company’s NanoChem Solutions Inc. subsidiary specializes in biodegradable, water-soluble products utilizing thermal polyaspartate (TPA) biopolymers. TPA beta-proteins are manufactured from the common biological amino acid, L-aspartic and have wide usage including scale inhibitors, detergent ingredients, water treatment and crop enhancement. The other divisions manufacture energy and water conservation products for drinking water, agriculture, industrial markets and swimming pools throughout the world. FSI is the developer and manufacturer of WaterSavrTM, the world’s first commercially viable water evaporation retardant. WaterSavrTM reduces evaporation by up to 30% on reservoirs, lakes, aqueducts, irrigation canals, ponds, and slow moving rivers. HeatsavrTM, a “liquid blanket” evaporation retardant for the commercial swimming pool and spa markets, reduces energy costs by 15% to 40% and can result in reduced indoor pool humidity.

Safe Harbor Provision

The Private Securities Litigation Reform Act of 1995 provides a “Safe Harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward looking statement with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Flexible Solutions International
206 – 920 Hillside Ave, Victoria, BC, V8T 1Z8 CANADA

Company Contact:

Jason Bloom
Tel: 250.477.9969
Toll Free: 800.661.3560
Fax: 250.477.9912
Email: info@flexiblesolutions.com

If you have received this news release by mistake or if you would like to be removed from our update list, please reply to: Danielle@flexiblesolutions.com

To find out more information about Flexible Solutions and our products, please visit www.flexiblesolutions.com.

SOURCE: Flexible Solutions International, Inc.

ReleaseID: 460857